Yükleniyor... / Loading...
This study looks at the gene expression (transcriptional) profile of peripheral blood cells in patients experiencing chronic kidney and lung transplant rejection, and how it relates to their response to extracorporeal photopheresis. It includes patients aged 18 and over with biopsy-proven kidney transplant rejection or chronic lung allograft dysfunction who are eligible for this treatment. It is a study without an assigned phase; it is not currently recruiting but is still ongoing (active, not recruiting).
The summary above is a plain-language rendering of the official record. The original English title is shown for reference.
Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.
Inclusion Criteria: * Age ≥ 18 years * Kidney transplant recipients with biopsy-proven AMCR * Lung transplant recipients with CLAD, defined as a persistent decline in FEV1 ≥ 20% compared with post-transplant baseline in the absence of other causes * Patients receiving standard immunosuppressive therapy and eligible for Extracorporeal Photoapheresis (ECP) * Ability to provide informed consent Exclusion Criteria: * Active infection or uncontrolled comorbidities that contraindicate ECP * Pregnancy or breastfeeding * Participation in another interventional trial that could interfere with outcomes * Inability to comply with study procedures Additional Notes: * Both prevalent and incident cases may be included (ambispective design). * Patients will be followed longitudinally for clinical outcomes, donor-specific antibodies, and gene expression profiling at baseline, 6 months, and 12 months.